Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats
My Vet Candy My Vet Candy

Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats

PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats.

Read More
The Feline Veterinary Medical Association and Merck Animal Health Champion Future Leaders in Feline Medicine
My Vet Candy My Vet Candy

The Feline Veterinary Medical Association and Merck Animal Health Champion Future Leaders in Feline Medicine

The Feline Veterinary Medical Association (FelineVMA) and Merck Animal Health are delighted to announce the 2025 Scholarships for Academic Excellence in Feline Healthcare recipients. This year’s recipients are Holly Kessler, The Ohio State University, Class of 2027, and Claire Stratton, Colorado State University, Class of 2026. Both recipients receive a $10,000 scholarship and a complimentary registration to the 2025 FelineVMA Annual Conference for their passion for feline medicine and a desire to elevate feline healthcare.

Read More